These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 21234720

  • 1. Optimal therapy in hypertensive subjects with diabetes mellitus.
    Reboldi G, Gentile G, Angeli F, Verdecchia P.
    Curr Atheroscler Rep; 2011 Apr; 13(2):176-85. PubMed ID: 21234720
    [Abstract] [Full Text] [Related]

  • 2. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.
    Reboldi G, Gentile G, Angeli F, Verdecchia P.
    Vasc Health Risk Manag; 2009 Apr; 5(1):411-27. PubMed ID: 19475778
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antihypertensive treatment and multifactorial approach for renal protection in diabetes.
    Fioretto P, Solini A.
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S18-21. PubMed ID: 15938027
    [Abstract] [Full Text] [Related]

  • 6. Target Blood Pressure in Patients with Diabetes: Asian Perspective.
    Park S, Kario K, Park CG, Huang QF, Cheng HM, Hoshide S, Wang JG, Chen CH, Characteristics On the ManagEment of Hypertension in Asia-Morning Hypertension Discussion Group (COME Asia MHDG).
    Yonsei Med J; 2016 Nov; 57(6):1307-11. PubMed ID: 27593856
    [Abstract] [Full Text] [Related]

  • 7. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ, Lewis JB.
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [Abstract] [Full Text] [Related]

  • 8. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Mar; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 9. [Antihypertensive treatment in type II diabetes and diabetic nephropathy].
    Chantrel F, Bouiller M, Kolb I, Hannedouche T.
    Nephrologie; 2000 Mar; 21(2):47-55. PubMed ID: 10798204
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.
    Ann Intern Med; 2003 Apr 01; 138(7):542-9. PubMed ID: 12667024
    [Abstract] [Full Text] [Related]

  • 11. Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage.
    Coca A.
    Expert Rev Cardiovasc Ther; 2007 Mar 01; 5(2):147-59. PubMed ID: 17338661
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance.
    Fleg JL, Evans GW, Margolis KL, Barzilay J, Basile JN, Bigger JT, Cutler JA, Grimm R, Pedley C, Peterson K, Pop-Busui R, Sperl-Hillen J, Cushman WC.
    Hypertension; 2016 Oct 01; 68(4):888-95. PubMed ID: 27504006
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. ESH-ESC guidelines for the management of hypertension.
    Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, Mancia G, Poulter N, Rahn KH, Rodicio JL, Ruilope LM, Staessen J, van Zwieten P, Waeber B, Williams B.
    Herz; 2006 Jun 01; 31(4):331-8. PubMed ID: 16810473
    [Abstract] [Full Text] [Related]

  • 18. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
    Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, BENEDICT Study Group.
    J Am Soc Nephrol; 2006 Dec 01; 17(12):3472-81. PubMed ID: 17082240
    [Abstract] [Full Text] [Related]

  • 19. Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
    Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OE.
    Hypertension; 2016 Dec 01; 68(6):1355-1364. PubMed ID: 27977392
    [Abstract] [Full Text] [Related]

  • 20. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
    Croom KF, Curran MP, Goa KL, Perry CM.
    Drugs; 2004 Dec 01; 64(9):999-1028. PubMed ID: 15101793
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.